- Conditions
- Renal Artery Stenosis
- Interventions
- Gadoterate meglumine (Dotarem), Time of Flight Magnetic Resonance Angiography
- Drug · Other
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Transient Severe Arterial Phase Motion
- Interventions
- gadoxetate disodium, gadoterate dimeglumine, Saline
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Interstitial Lung Disease
- Interventions
- [68Ga]CBP8, Dotarem
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Disease
- Interventions
- Dotarem, Time of Flight
- Drug · Other
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis
- Interventions
- [68Ga]CBP8, Gadoterate Meglumine
- Drug
- Lead sponsor
- Peter Caravan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vascular Diseases
- Interventions
- Dotarem
- Diagnostic Test
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Steno-occlusive Disease
- Interventions
- gadopiclenol, Gadoterate meglumine (Dotarem)
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Evanston, Illinois + 3 more
- Conditions
- Renal Insufficiency
- Interventions
- Not listed
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- Not listed
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 4
- States / cities
- Saginaw, Michigan • St Louis, Missouri • Philadelphia, Pennsylvania + 1 more
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, E-cigarettes
- Interventions
- E-cigarette, Sham, Hyperpolarized 3-Helium, Gadolinium
- Device · Other · Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years to 35 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn Disease
- Interventions
- Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw, Glucagon, Imaging, Oral contrast media application
- Drug · Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Pulmonary Embolism
- Interventions
- Gadolinium
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 20 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Magnetic Resonance Imaging Contrast Agents
- Interventions
- Magnevist, Dotarem, Gadovist
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 500 participants
- Timeline
- 1990 – 2019
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Primary Brain Tumor
- Interventions
- Dotarem®, Gadovist®/Gadavist®
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
- Conditions
- Breast Diseases
- Interventions
- Gadoterate meglumine, Gadobutrol
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
- Interventions
- Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Contrast Media Allergy
- Interventions
- Gadolinium
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 56 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
- Interventions
- Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
- Drug · Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Diagnostic Self Evaluation, Central Nervous System Diseases
- Interventions
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
- Conditions
- Heart Failure, Myocardial Infarction, Left Ventricular Hypertrophy
- Interventions
- Diffusion Tensor MRI (DTI), Gadolinium DOTA Meglumine
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Glioma
- Interventions
- Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging, Positron Emission Tomography
- Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Indian Wells, California • Orange, California • Miami, Florida + 5 more
- Conditions
- Gadolinium, MultiHance, Dotarem, Magnetic Resonance Imaging, Gadolinium Retention
- Interventions
- Pre-operative MRI with Dotarem, Pre-operative MRI with MultiHance, Surgery
- Drug · Procedure
- Lead sponsor
- Donna Roberts
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more